ºÚÁÏÍø

James Hendrix

Alzheimer’s Association, Chicago, IL, USA

Biography

Dr James A. Hendrix, Ph.D., is the Chief Scientific Officer for LuMind IDSC. As the Chief Scientific Officer, Dr. Hendrix directs scientific initiatives for LuMind IDSC. A critical element of his role is to establish the nationwide Down Syndrome – Clinical Trial Network (DS-CTN) and to oversee the first clinical trial in the DS-CTN, the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. 

Publications

Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases

Alzheimer’s disease (AD) and Parkinson’s disease (PD) pose significant challenges for successful development of new therapies, with anextremely high drug trial failure rate and yet no approved disease modifying drugs available. Given the magnitude of the challenges, it has become clear that larger collaborations and multi-partner joint ... Read More»

Diane Stephenson, Martha Brumfield, Klaus Romero, Janet Woodcock, Issam Zineh, Eric M Reiman, Caroline Tanner, Richard Mohs, Walter Koroshetz, Timothy Nicholas, Lisa J Bain, Derek Hill, Les Shaw, Johan Luthman, Michael Ropacki, Richard Meibach, Peter Loupos, Ken Marek, James Hendrix, Eric Karran, George Vradenburg, Keiju Motohashi, Jesse M Cedarbaum and Mark Forrest Gordon

Conference Proceeding: J Alzheimers Dis Parkinsonism 2015, 5:183

DOI:

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article